Why Exelixis Stock Is Skyrocketing Today
Shares of (NASDAQ: EXEL) were skyrocketing 18.5% higher at 11:05 a.m. ET on Wednesday. The huge gain came after the drugmaker announced its 2025 first-quarter results Tuesday evening.
Exelixis reported Q1 revenue of $555.4 million, up 30.6% year over year. This result handily topped the consensus revenue estimate of $503 million.
The company posted net income of $159.6 million, or $0.55 per diluted share, based on generally accepted accounting principles (GAAP). Non-GAAP earnings were $179.6 million, or $0.62 per diluted share. This reflected a significant improvement from non-GAAP earnings of $52 million, or $0.17 per diluted share, in the prior-year period. It also blew past Wall Street's average Q1 adjusted earnings estimate of $0.42 per share.
Source Fool.com
Exelixis Inc. Aktie
Klares Signal: Exelixis Inc. wird ausschließlich zum Kauf empfohlen.
Das Kursziel von 40 € für Exelixis Inc. weist auf ein leicht positives Potenzial gegenüber dem aktuellen Kurs von 37.55 € hin.
